Mylan launches authorized generic of Ampyraź tablets
Mylan announced the U.S. launch of Dalfampridine ER Tablets, 10 mg, the authorized generic version of Acorda's Ampyraź, which is indicated to improve walking in adult patients with multiple sclerosis. Acorda's U.S. Patent No. 5,540,938, previously upheld by the District Court, expired July 30, 2018. September 21, 2018